Balapiravir

Balapiravir
Legal status

Legal status	Investigational New Drug
Identifiers
IUPAC name [(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-azido-3,4-bis(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate
CAS Number	690270-29-2^Y
PubChem (CID)	11691726
ChemSpider	9866453
KEGG	D09582
ChEMBL	CHEMBL550936
Chemical and physical data
Formula	C₂₁H₃₀N₆O₈
Molar mass	494.497
3D model (Jmol)	Interactive image
SMILES O=c1nc(N)ccn1C2OC(N=[N+]=[N-])(COC(=O)C(C)C)C(OC(=O)C(C)C)C2OC(=O)C(C)C
InChI InChI=1S/C21H30N6O8/c1-10(2)17(28)32-9-21(25-26-23)15(34-19(30)12(5)6)14(33-18(29)11(3)4)16(35-21)27-8-7-13(22)24-20(27)31/h7-8,10-12,14-16H,9H2,1-6H3,(H2,22,24,31)/t14-,15+,16-,21-/m1/s1 Key:VKXWOLCNTHXCLF-DXEZIKHYSA-N

Balapiravir (R-1626, Ro4588161) is an experimental antiviral drug which acts as a polymerase inhibitor. There were efforts to develop it as a potential treatment for hepatitis C, and it was subsequently also studied in Dengue fever, but was not found to be useful. Lower doses failed to produce measurable reductions in viral load, while higher doses produced serious side effects such as lymphopenia which precluded further development of the drug.^[1] Subsequent research found that excess cytokine production triggered by Dengue virus infection prevented the conversion of the balapiravir prodrug to its active form, thereby blocking the activity of the drug.^[2]

References

↑ "A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients.". Ncbi.nlm.nih.gov. Retrieved 7 May 2014.
↑ Chen Y, et al. Activation of Peripheral Blood Mononuclear Cells by Dengue Virus Infection Depotentiates Balapiravir. J. Virol. 2014; 88(3):1740-1747. doi: 10.1128/JVI.02841-13

This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.